{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Beinat C"],"funding":["NIH NINDS Research Education Grant","Ben and Catherine Ivy Foundation","NINDS NIH HHS","NCI NIH HHS","NIH NCI"],"pagination":["6467-6478"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8639752"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(23)"],"pubmed_abstract":["<h4>Purpose</h4>Pyruvate kinase M2 (PKM2) catalyzes the final step in glycolysis, a key process of cancer metabolism. PKM2 is preferentially expressed by glioblastoma (GBM) cells with minimal expression in healthy brain. We describe the development, validation, and translation of a novel PET tracer to study PKM2 in GBM. We evaluated 1-((2-fluoro-6-[<sup>18</sup>F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine ([<sup>18</sup>F]DASA-23) in cell culture, mouse models of GBM, healthy human volunteers, and patients with GBM.<h4>Experimental design</h4>[<sup>18</sup>F]DASA-23 was synthesized with a molar activity of 100.47 ± 29.58 GBq/μmol and radiochemical purity >95%. We performed initial testing of [<sup>18</sup>F]DASA-23 in GBM cell culture and human GBM xenografts implanted "],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2-Induced Glycolytic Reprogramming in Glioblastoma."],"pmcid":["PMC8639752"],"funding_grant_id":["R01 CA216054–01","R01 CA216054","5R25NS065741–07","R25 NS065741","F30 CA228215","F30CA228215"],"pubmed_authors":["Murty S","Liu DD","Granucci M","Recht LD","Massoud TF","Shen B","James ML","Gandhi H","He JQ","Halbert K","Warnock GI","Davidzon G","Thomas R","Beinat C","Patel CB","Hayden-Gephart M","Johnson E","Gambhir SS","Castillo JB","Weissman I","Uchida N","Chu P","Park JH","Haywood T","Buccino P","Born DE","Nagpal S","Holley D","Phillips M","Naya L","Sinha R","Koran MEI","Iagaru A","Reyes ST","Khalighi M","Alam IS"],"additional_accession":[]},"is_claimable":false,"name":"A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2-Induced Glycolytic Reprogramming in Glioblastoma.","description":"<h4>Purpose</h4>Pyruvate kinase M2 (PKM2) catalyzes the final step in glycolysis, a key process of cancer metabolism. PKM2 is preferentially expressed by glioblastoma (GBM) cells with minimal expression in healthy brain. We describe the development, validation, and translation of a novel PET tracer to study PKM2 in GBM. We evaluated 1-((2-fluoro-6-[<sup>18</sup>F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine ([<sup>18</sup>F]DASA-23) in cell culture, mouse models of GBM, healthy human volunteers, and patients with GBM.<h4>Experimental design</h4>[<sup>18</sup>F]DASA-23 was synthesized with a molar activity of 100.47 ± 29.58 GBq/μmol and radiochemical purity >95%. We performed initial testing of [<sup>18</sup>F]DASA-23 in GBM cell culture and human GBM xenografts implanted ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2026-05-09T20:13:43.802Z","creation":"2025-02-19T00:56:33.785Z"},"accession":"S-EPMC8639752","cross_references":{"pubmed":["34475101"],"doi":["10.1158/1078-0432.CCR-21-0544","10.1158/1078-0432.ccr-21-0544"]}}